Browsing by Author "Matta-Coelho, C"
Now showing 1 - 10 of 16
Results Per Page
Sort Options
- 20-year retrospective study of clinically non-functioning pituitary adenomas - a single center experiencePublication . Matta-Coelho, C; Ramos, R; Almeida, R; Marques, O
- Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implicationsPublication . Paredes, S; Matta-Coelho, C; Monteiro, AM; Brás, A; Marques, O; Alves, M; Ribeiro, LType 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and the cardiovascular effect of antidiabetic drugs are today critical medical issues, with the prevalence of T2DM in particular showing a steep increase worldwide, mainly due to unhealthy lifestyle habits. T2DM in association with obesity and other cardiovascular risk factors, results in the development of CVD, the leading cause of morbidity and mortality in patients with T2DM. Thus, treatment of T2DM is an individualized and complex challenge in which targeting cardiovascular risk factors is an important component in the decision making. Given the cardiovascular adverse events associated with rosiglitazone, both the Food and Drug Administration and the European Medicines Agency currently require the demonstration of cardiovascular safety of new antidiabetic drugs. Consequently, clinical trials to guarantee their cardiovascular safety are now obligatory. This review aims to summarize the available evidence on the cardiovascular effects and safety of the major drugs used in T2DM treatment and also to provide an overview of upcoming and ongoing clinical trials in this field. Our belief is that this review will be of substantial assistance to all medical doctors who are treating diabetic patients, namely primary care physicians, internal medicine doctors, endocrinologists, diabetologists and less well experienced personnel such as young doctors in training.
- Descompensação metabólica da diabetes e tempestade tiroideia –causa ou consequência?Publication . Monteiro, AM; Matta-Coelho, C; Marques, O
- Diabetes gestacional - a experiência do hospital de braga versus outros centros do registo nacional da diabetes gestacionalPublication . Matta-Coelho, C; Monteiro, AM; Lopes-Pereira, M; Souto, SB
- Hiperglicemia intermédiaPublication . Matta-Coelho, C; Souto, SB; Marques, O
- Hyperosmolar hyperglycaemic state and diabetic ketoacidosis – a 5 year retrospective study in a university hospitalPublication . Matta-Coelho, C; Nunes, C; Fernandes, V; Pinto, ML; Souto, SB; Marques, O
- Iron Deficiency and Obesity - Are we Diagnosing with Appropriate Indicators?Publication . Monteiro, AM; Fernandes, V; Matta-Coelho, C; Paredes, Sílvia; Pereira, ML; Marques, O; Alves, MINTRODUCTION: We aim to define the iron deficiency prevalence and eventual differences between obese patients with and without metabolic syndrome. MATERIAL AND METHODS: Analysis of patients evaluated at multidisciplinary consultation of obesity in our institution between 2013 and 2015 (n = 260). Iron deficiency: ferritin levels < 15 ng/mL. EXCLUSION CRITERIA: prior bariatric surgery; lack of ferritin or hemoglobin determinations. RESULTS: We analyzed data from 215 patients (84.2% female) with a mean age of 42.0 ± 10.3 years. The median body mass index was 42.5 (40.0 - 46.8) kg/m2 and 52.1% had metabolic syndrome. Iron deficiency was present in 7.0%, with no differences between genders or between patients with or without metabolic syndrome. Hypertension was associated with lower prevalence of iron deficiency. Type 2 diabetes and hypertension patients had higher levels of ferritin. The multivariate analysis showed that metabolic syndrome and increasing body mass index were predictive of higher risk of iron deficiency while hypertension predicted lower odds of iron deficiency. DISCUSSION: The prevalence of iron deficiency was similar in other published studies. Iron deficiency may be underdiagnosed if based only on ferritin concentrations. In our study, diabetes and hypertension appear to contribute to the increase in ferritin levels described in obesity. CONCLUSION: Ferritin may not be a reliable index for evaluating iron stores in obese patients, particularly when associated with comorbidities such as type 2 diabetes and hypertension. Further studies are needed to guide the diagnosis and iron supplementation in these patients.
- Metabolically healthy obesity characterization and relation with vitamin D - study in a bariatric surgery populationPublication . Matta-Coelho, C; Fernandes, V; Monteiro, AM; Paredes, S; Multidisciplinary Group for Surgical Management of Obesity; Souto, SB; Correia, F
- Mucormicose rinocerebrorbitária e diabetes mellitus – a propósito de um caso clínico.Publication . Matta-Coelho, C; Amorim, J; Carvalho, SD; Silva, D; Monteiro, AM; Souto, SB; Marques, O
- Primary hyperaldosteronism by Conn’s Syndrome – clinical case discussionPublication . Matta-Coelho, C; Monteiro, AM; Fernandes, V; Souto, SB; Manso, F; Marques, O